Advertisement

Topics

Latest "Alimera Sciences Present 29th Annual ROTH Conference" News Stories

17:44 EDT 24th September 2018 | BioPortfolio

Here are the most relevant search results for "Alimera Sciences Present 29th Annual ROTH Conference" found in our extensive news archives from over 250 global news sources.

More Information about Alimera Sciences Present 29th Annual ROTH Conference on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alimera Sciences Present 29th Annual ROTH Conference for you to read. Along with our medical data and news we also list Alimera Sciences Present 29th Annual ROTH Conference Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alimera Sciences Present 29th Annual ROTH Conference Companies for you to search.

Showing "Alimera Sciences Present 29th Annual ROTH Conference" News Articles 1–25 of 14,000+

Monday 24th September 2018

Brazil court strips Gilead of hepatitis C drug patent

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.


Books-A-Million and Children’s of Alabama Partner to Celebrate 4th Annual Superhero Month

Children’s of Alabama hospital patients honored with super celebrations, September 28 – October 25 Superheroes unite! Books-A-Million and Children’s of Alabama welcome the return of their fourth annual Superhero Month to bring a smile to the lives of ill and injured children. From September 28 – October 25, ‘The Power of Children’s’ initi...

Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY. President and Chief Executive Officer, Dan Browne, is scheduled to prese...


TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung Cancer

Ongoing Antitumor Activity and Durable Responses Observed across Multiple Dose Cohorts in both TKI-naïve and TKI-pretreated ROS1 Positive NSCLC Patients Overall Response Rate, Based on Blinded Central Review, is 80 Percent in TKI-naïve ROS1+ Patients and 23 Percent in Patients Treated with 1 Prior TKI TP Therapeutics, a privately held...

TCT.18: Anticipated OAC-ALONE results ‘underpowered, inconclusive’

OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.

Diabetic Retinopathy - A Drug Pipeline Analysis Report by Technavio

Technavio has announced their latest drug pipeline analysis report on diabetic retinopathy. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of dia

Brazil court strips Gilead hepatitis drug patent, politician says

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

Anthem Blue Cross Blue Shield Rated Among Top Health Plans in Maine by NCQA

Anthem Blue Cross and Blue Shield in Maine received a rating of 4.5 out of 5 in the recently released National Committee for Quality Assurance (NCQA) Private Health Insurance Plan Ratings 2017-2018, making it a top-ranked plan in the state. The NCQA, a nonprofit organization dedicated to improving health care quality, publicly released its 2018-19...

Survey: Nearly One-Third of Seniors Don’t Feel Socially Engaged

Humana Launches Programming to Encourage Socialization, Group Activity during Active Aging Week New findings from leading health and well-being company Humana Inc. (NYSE: HUM) show that nearly one-third (31 percent) of Americans aged 65 and older say they don’t feel socially engaged. However, a majority of respondents say it is important to establish...

Medtronic Builds on TAVR Clinical Evidence Portfolio with Five-Year CoreValve Durability Data and Complete Two-Year Outcomes in Intermediate Risk Aortic Stenosis Patients

TCT18: New Five-Year Data with CoreValve TAVR System Suggests Durability Over Time, While Complete Results from the SURTAVI Trial Show Benefits of TAVR in Intermediate Risk Patients DUBLIN and SAN DIEGO - September 24, 2018 - Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced new data presented at the 30th Transcatheter Cardiovascular Therapeutics (TC...

Ping An Unveils AI Technology at International Maritime Silk Road Forum

Empowers Smart City and Healthcare HONG KONG and SHANGHAI, Sept. 24, 2018 /PRNewswire/ -- The second 21st Century Maritime Silk Road Forum on International Communication was held in Zhuhai in 19-21 September. Jean-Pierre Raffarin, former Prime Minister of France and Thomas J. Sargent, the 2011 Nobel Prize winner for Economics delivered keynote speeches at the main forum. As a leading compan...

Biotechnology Industry Data Survey Shows Competition for Investment and Talent Remain Real

Poised as a vital component of Canada’s push to develop more knowledge-intensive industries, Canada’s biotechnology sector is composed of many early-stage companies that are expecting significant growth in the future. The survey results underscore the reality that the search for talent and investment will continue as an important industry priority for ...

Gilead to launch generic versions of its hepatitis drugs

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer

Centrexion Therapeutics Corporation, a company focused on developing novel, non-opioid and non-addictive therapies for the treatment of chronic pain, today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company. “We are very pleased to have Andrew join the Centrexion leadership team,...

EU-OSHA Joins the Fight Against Occupational Cancer at Austrian EU Presidency Conference

On 24 - 25 September, the Austrian Presidency of the Council of the EU is hosting a high-level conference, Fight against Occupational Cancer, in Vienna. A range of speakers and participants, including politicians, social partners and experts in the field explore ways of protecting Europe’s workers from exposure to carcinogens at work. BILBAO, Spain (PRWEB UK) 24 September 2018 The conference pr...

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni for the Treatment of Chronic Hepatitis C

Gilead Sciences (NASDAQ:GILD) plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. As quoted in the press release: Since the launch of Gilead’s first HCV medic...

Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer

F. Hoffmann-La Roche Ltd / Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Data will be presented at the 2018 World C...

Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Spectrum will host a live webcast today at 4:30 p.m. Eastern/1:30 p.m. Pacific Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations...

ComPsych® Corp. Announces 2018 Health at WorkSM Award Winners: Comcast NBCUniversal, NBA, City of Mesa, Fresenius Medical Care North America, Montgomery County, Council on Foreign Relations and Nuru International

ComPsych announced today winners of its 14th-annual Health at Work Awards, honoring organizations that support employees with exceptional wellness and well-being programs. ComPsych Corporation is the world’s largest provider of employee assistance programs and is the pioneer and worldwide leader of fully integrated EAP, behavioral health, wellness, ...

LabCorp Teams up with Operation Airdrop to Deliver Much-Needed Supplies to North Carolina Communities Devastated by Hurricane Florence

Over the weekend, LabCorp® (NYSE: LH) in coordination with Operation Airdrop delivered approximately 25,000 pounds of water, food, dog food, diapers, and other relief supplies as well as 1,000 hot meals aboard three of LabCorp’s Pilatus PC-12 cargo aircraft to aid in recovery efforts following Hurricane Florence. This press release features multimedia. V...

Morae Global Managing Director Danish Butt to Speak at Mitratech’s Interact 2018 Conference

Leader of Morae’s Technology-Enabled Transformation practice to address “Automating Legal Service Request to Increase Customer Satisfaction and Operational Efficiency” HOUSTON (PRWEB) September 24, 2018 Morae Global Corporation, a full-service, technology-enabled, integrated solution provider for the legal and compliance function, announced that Danish Butt, Managing Director, will speak at...

Anthem Blue Cross Blue Shield Rated Top Health Plan in Connecticut by NCQA

Anthem Blue Cross and Blue Shield in Connecticut received a rating of 4.5 out of 5 in the recently released National Committee for Quality Assurance (NCQA) Private Health Insurance Plan Ratings 2018-2019, making it the top-ranked health plan in the state. The NCQA, a nonprofit organization dedicated to improving healthcare quality, publicly releas...

Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer

-- Updated subgroup analysis from ongoing phase 1 study of [fam-] trastuzumab deruxtecan (DS-8201) demonstrated a confirmed overall response rate of 72.7 percent and a disease control rate of 100 ...

Current @IASLC President @giorgioscaglio3 at #WCLC2018 Plenary discussing society's commitment to patients with lung cancer around the world & leading largest conference on lung cancer, developing new researchers, education for docs & pts, & many other in

Current @IASLC President @giorgioscaglio3 at #WCLC2018 Plenary discussing society's commitment to patients with lung cancer around the world & leading largest conference on lung cancer, developing new researchers, education for docs & pts, & many other initiatives. #LCSM

Only 1 week left for Big Data and Cancer Precision Medicine! Join emerging and established leaders in cancer precision medicine and data sciences. REGISTER TODAY! https://go.nature.com/2M1Z226  #bigdatacpm18 @DanaFarber @Nature @NatureBiotech @natBME

Only 1 week left for Big Data and Cancer Precision Medicine! Join emerging and established leaders in cancer precision medicine and data sciences. REGISTER TODAY! https://go.nature.com/2M1Z226  #bigdatacpm18 @DanaFarber @Nature @NatureBiotech


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks